within Pharmacolibrary.Drugs.ATC.J;

model J05AF13
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.16,
    Cl             = 1.4783333333333333,
    adminDuration  = 600,
    adminMass      = 0.025,
    adminCount     = 1,
    Vd             = 0.096,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.015233333333333333,
    Tlag           = 21.599999999999998
  );

  annotation(Documentation(
    info ="<html><body><p>Tenofovir alafenamide is an antiretroviral prodrug of tenofovir used for the treatment of HIV-1 infection and chronic hepatitis B in adults and adolescents. It has improved plasma stability and delivers the active drug at lower doses with reduced systemic toxicity compared to tenofovir disoproxil fumarate. Tenofovir alafenamide is approved and widely used today.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult subjects after oral administration of tenofovir alafenamide 25 mg once daily.</p><h4>References</h4><ol><li><p>Thurman, AR, et al., &amp; Doncel, GF (2021). Safety and Pharmacokinetics of a Tenofovir Alafenamide Fumarate-Emtricitabine based Oral Antiretroviral Regimen for Prevention of HIV Acquisition in Women: A Randomized Controlled Trial. <i>EClinicalMedicine</i> 36 100893–None. DOI:<a href=&quot;https://doi.org/10.1016/j.eclinm.2021.100893&quot;>10.1016/j.eclinm.2021.100893</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/34041459/&quot;>https://pubmed.ncbi.nlm.nih.gov/34041459</a></p></li><li><p>Scott, LJ, &amp; Chan, HLY (2017). Tenofovir Alafenamide: A Review in Chronic Hepatitis B. <i>Drugs</i> 77(9) 1017–1028. DOI:<a href=&quot;https://doi.org/10.1007/s40265-017-0754-9&quot;>10.1007/s40265-017-0754-9</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/28493172/&quot;>https://pubmed.ncbi.nlm.nih.gov/28493172</a></p></li><li><p>Rajoli, RKR, et al., &amp; Siccardi, M (2020). Predicting Pharmacokinetics of a Tenofovir Alafenamide Subcutaneous Implant Using Physiologically Based Pharmacokinetic Modelling. <i>Antimicrobial agents and chemotherapy</i> 64(8) –. DOI:<a href=&quot;https://doi.org/10.1128/AAC.00155-20&quot;>10.1128/AAC.00155-20</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/32423957/&quot;>https://pubmed.ncbi.nlm.nih.gov/32423957</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end J05AF13;
